114 related articles for article (PubMed ID: 11337570)
1. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency?
Kropp J; Wencker M; Hotze A; Banik N; Hübner GE; Wunderlich G; Ulbrich E; Konietzko N; Biersack HJ
J Nucl Med; 2001 May; 42(5):744-51. PubMed ID: 11337570
[TBL] [Abstract][Full Text] [Related]
2. Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis.
Häussermann S; Winnips C; Edelman J; Kappeler D; Herpich C; Ehlich H; Zanker D; Kietzig C; Sommerer K
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):242-50. PubMed ID: 26669827
[TBL] [Abstract][Full Text] [Related]
3. Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis.
Siekmeier R
Eur J Med Res; 2010 Nov; 15 Suppl 2(Suppl 2):164-74. PubMed ID: 21147646
[TBL] [Abstract][Full Text] [Related]
4. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
5. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices.
Brand P; Beckmann H; Maas Enriquez M; Meyer T; Müllinger B; Sommerer K; Weber N; Weuthen T; Scheuch G
Eur Respir J; 2003 Aug; 22(2):263-7. PubMed ID: 12952258
[TBL] [Abstract][Full Text] [Related]
6. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers.
Vogelmeier C; Kirlath I; Warrington S; Banik N; Ulbrich E; Du Bois RM
Am J Respir Crit Care Med; 1997 Feb; 155(2):536-41. PubMed ID: 9032191
[TBL] [Abstract][Full Text] [Related]
7. Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers.
Virgolini I; Kurtaran A; Leimer M; Smith-Jones P; Agis H; Angelberger P; Kletter K; Valent P; Linkesch W; Eichler HG
J Nucl Med; 1997 Sep; 38(9):1475-81. PubMed ID: 9293812
[TBL] [Abstract][Full Text] [Related]
8. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
9. Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition.
Biddiscombe MF; Meah SN; Underwood SR; Usmani OS
J Aerosol Med Pulm Drug Deliv; 2011 Jun; 24(3):165-73. PubMed ID: 21453048
[TBL] [Abstract][Full Text] [Related]
10. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
11. [Difficulties in controlled inhalation of alpha 1-protease inhibitor].
Brand P; Maas Enriquez M; Meyer T; Scheuch G; Weber N
Pneumologie; 2003 Mar; 57(3):153-8. PubMed ID: 12632295
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
Franciosi AN; McCarthy C; McElvaney NG
Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
[TBL] [Abstract][Full Text] [Related]
13. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency.
Brand P; Schulte M; Wencker M; Herpich CH; Klein G; Hanna K; Meyer T
Eur Respir J; 2009 Aug; 34(2):354-60. PubMed ID: 19251783
[TBL] [Abstract][Full Text] [Related]
14. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706
[TBL] [Abstract][Full Text] [Related]
15. Alpha1-antitrypsin augmentation therapy.
Pierce JA
Chest; 1997 Oct; 112(4):872-4. PubMed ID: 9377947
[No Abstract] [Full Text] [Related]
16. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
Campos MA; Kueppers F; Stocks JM; Strange C; Chen J; Griffin R; Wang-Smith L; Brantly ML
COPD; 2013 Dec; 10(6):687-95. PubMed ID: 23862647
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
Wencker M; Fuhrmann B; Banik N; Konietzko N;
Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of a Liquid Formulation of Alpha
Barker AF; Campos MA; Brantly ML; Stocks JM; Sandhaus RA; Lee D; Steinmann K; Lin J; Sorrells S
COPD; 2017 Dec; 14(6):590-596. PubMed ID: 28985109
[TBL] [Abstract][Full Text] [Related]
19. alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.
Stoller JK; Aboussouan LS
Thorax; 2004 Aug; 59(8):708-12. PubMed ID: 15282394
[TBL] [Abstract][Full Text] [Related]
20. Blood gases at rest and during exercise in patients with alpha1-Pi deficiency.
Wencker M; Konietzko N
Respir Med; 2000 Dec; 94(12):1177-83. PubMed ID: 11192953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
